10261-82-2

Basic information

• Product Name: 2-Hydroxy-1,5-naphthyridine
• Synonyms: 2-Hydroxy-1,5-naphthyridine;1,5-Naphthyridin-2(1H)-one;1,5-naphthyridin-2-ol;1,5-Naphthyridin-2(1H)
• CAS NO: 10261-82-2
• Molecular Formula: C₈H₆N₂O
• Molecular Weight: 146.14604
• Mol File: 10261-82-2.mol
• Article Data: 9

Chemical Properties

• Melting Point: 258 °C
• Boiling Point: 391.8 °C at 760 mmHg
• Flash Point: 190.8 °C
• Appearance: /
• Density: 1.267g/cm³
• Vapor Pressure: 2.4E-06mmHg at 25°C
• Refractive Index: 1.602
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 11.29±0.20(Predicted)
• CAS DataBase Reference: 2-Hydroxy-1,5-naphthyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Hydroxy-1,5-naphthyridine(10261-82-2)
• EPA Substance Registry System: 2-Hydroxy-1,5-naphthyridine(10261-82-2)

Safety Data

• Hazardous Substances Data: 10261-82-2(Hazardous Substances Data)

Usage

Uses

1,5-Naphthyridin-2(1H)-one is used as a reactant in the design of brain penetrant JNK inhibitors for prevention of neurodegeneration.

InChI:InChI=1/C8H6N2O/c11-8-4-3-6-7(10-8)2-1-5-9-6/h1-5H,(H,10,11)

Upstream product

• 17965-80-9 2-amino-1,5-naphthyridine 
• 7689-62-5 2-chloro-1,5-naphthyridine 
• 104829-97-2 ethyl 3-amino-2-pyridineacrylate 
• 462-08-8 pyridin-3-ylamine 
• 5350-93-6 6-Chloro-pyridin-3-ylamine 
• 56-81-5 glycerol 
• 6298-19-7 2-chloro-3-aminopyridine 
• 141-32-2 acrylic acid n-butyl ester 
• 7664-93-9 sulfuric acid 
• 33630-94-3 5-amino-2-hydroxypyridine 
• 7778-39-4 orthoarsenic acid 
• 1452561-63-5 (E)-methyl 3-(3-aminopyridin-2-yl)acrylate 
• 27017-69-2 2-methoxy-[1,5]-naphthyridine 
• 60058-16-4 4-hydroxy-1H-[1,5]naphthyridin-2-one 

Downstream Products

• 7689-62-5 2-chloro-1,5-naphthyridine 
• 64222-33-9 3-nitro-1H-[1,5]naphthyridin-2-one 
• 1309774-03-5 7-bromo-2-chloro-1,5-naphthyridine 
• 1422123-35-0 C₂₁H₂₂N₄O₃ 
• 1422123-99-6 C₂₂H₂₂N₆O 
• 1422124-32-0 C₂₁H₂₀N₆O 
• 1422124-72-8 C₂₁H₂₁N₅O₂ 
• 1422125-49-2 C₂₄H₂₅N₇O₄S 
• 1422125-93-6 C₂₂H₂₃N₇O 

Relevant articles and documents

Design and synthesis of brain penetrant selective JNK inhibitors with improved pharmacokinetic properties for the prevention of neurodegeneration

The SAR of a series of brain penetrant, trisubstituted thiophene based JNK inhibitors with improved pharmacokinetic properties is described. These compounds were designed based on information derived from metabolite identification studies which led to compounds such as 42 with lower clearance, greater brain exposure and longer half life compared to earlier analogs.

NOVEL SUBSTITUTED TRICYCLIC COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: Formula (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF

A compound represented by Formula [1] (in the formula, Z1 represents N, CH, or the like; X1 represents NH or the like; R1 represents a heteroaryl group or the like; each of R2, R3, and R4 represents a hydrogen atom, a halogen atom, an alkoxy group, or the like; and R5 represents a heteroaryl group or the like) or salt thereof.

HETEROBICYCLIC COMPOUNDS

Heterobicyclic compounds of Formula (I): or a pharmaceutically-acceptable salt, tautomer, or stereoisomer thereof, as defined in the specification, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, Huntington's Disease, and the like.